Appointment of liquidators (MVL)
Graegis Pharmaceuticals Limited enters members' voluntary liquidation
In short: Graegis Pharmaceuticals Limited (company no. 13680871) entered members' voluntary liquidation, a solvent and planned closure, according to a Appointment of liquidators (MVL) notice published in The London Gazette on 12 October 2026. The office holder is James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ, appointed 30 September 2026. The company's business: research and experimental development on biotechnology, trading from C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham, Cambridge, Cambridgeshire, CB22 3AT.
The notice announces that the members of Graegis Pharmaceuticals Limited have appointed James Hopkirk of Kreston Reeves LLP as liquidator for a members voluntary liquidation effective 30 September 2026.
Notice details
- Company
- GRAEGIS PHARMACEUTICALS LIMITED
- Company number
- 13680871
- Registered office
- C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, CB22 3FH
- Principal trading address
- C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham, Cambridge, Cambridgeshire, CB22 3AT
- Nature of business
- Research and experimental development on biotechnology
- Type of liquidation
- Members Voluntary Liquidation
- Date of appointment
- 30 September 2026
- Liquidator
- James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ
- Contact
- Mansi Thawani, 01634 899800, [email protected]
- Appointed by
- Members
- Appointment date
- 7 October 2026
What this notice means
A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.
Read more: What is Liquidation?.
All notices for Graegis Pharmaceuticals Limited
3 Gazette notices on record for company no. 13680871, newest first. The full history, with last filed accounts, is on the Graegis Pharmaceuticals Limited company record.
- Resolution for winding up (MVL) 12 Oct 2026
- Notices to creditors (MVL) 12 Oct 2026
How does this notice affect you?
Choose what applies and we'll point you at the right next step.
A written-off invoice rarely stops at the company that failed. The supplier left short is often the next business in difficulty — and the earlier that's dealt with, the more options stay open. If GRAEGIS PHARMACEUTICALS LIMITED owed you money, it's worth checking where that leaves you.
Unpaid wages, holiday pay and statutory redundancy are claimed from the government's Redundancy Payments Service, not from K2. The insolvency practitioner named in this notice should send you a case reference — you'll need it to claim.
K2's founder has turned around UK businesses since 1990, and K2 has backed and restructured them since 2001, including buying trade and assets out of distress. These situations move in days rather than months, so if you're looking at GRAEGIS PHARMACEUTICALS LIMITED or something similar, start the conversation early.
A members' voluntary liquidation is a solvent, orderly closure — often part of retirement, a group restructure, or moving on to the next venture. K2's founder has advised UK company directors since 1990 on restructuring and what comes next. If that's on your horizon, talk to us.
Related guidance
Free, practical guides from K2 on what this kind of notice means for directors.
More liquidation notices
Frequently asked questions
Is Graegis Pharmaceuticals Limited in financial difficulty?
No — this is a solvent process. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The London Gazette published a Appointment of liquidators (MVL) for Graegis Pharmaceuticals Limited (company no. 13680871) on 12 October 2026.
What does a Appointment of liquidators (MVL) mean?
A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.
Who is dealing with the liquidation?
The office holder named in the notice: James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ, appointed 30 September 2026. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number.
Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.